Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Yangyin Jiedu Fang is a Traditional Chinese Medicine (TCM) herbal formula designed to address the TCM pattern of 'Qi and Yin deficiency' accompanied by 'toxic heat.' It is primarily utilized as an adjuvant therapy in oncology, particularly for non-small cell lung cancer (NSCLC) and gastric cancer, to enhance the efficacy of conventional treatments like chemotherapy and targeted therapy while mitigating treatment-related side effects. The formula typically comprises a combination of herbs such as *Astragalus membranaceus* (Huangqi), *Panax quinquefolius* (Xiyangshen), *Ophiopogon japonicus* (Maidong), and *Hedyotis diffusa* (Baihuasheshecao). Its pharmacological mechanism involves multi-target actions, including immunomodulation, inhibition of tumor angiogenesis via the suppression of pro-angiogenic factors, and the induction of apoptosis in malignant cells through the activation of caspase pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yiqi yangyin jiedu fang.